Luke R. Sponholz
Olena Slinchenkova
Sumeet Singh-Tan
Mark Shlomovich
Albumin Dialysis
Care of children before and after solid organ transplantation
<p>Mark Shlomovich, MD, is Director, Extracorporeal Liver Support and Director, Pediatric Critical Care Transport at Children’s Hospital at Montefiore and Assistant Professor, Pediatrics at Montefiore-Einstein. Dr. Shlomovich’s clinical focus is on the care of critically ill children with abdominal organ failure, transplantation and post-surgical care. He also focuses on the safe transportation of critically ill children.</p><p>In 2006, Dr. Shlomovich earned his Bachelor of Science in biology from Towson University. He then attended University of Connecticut School of Medicine earning his Doctor of Medicine in 2010. His postgraduate training began at SUNY Downstate Medical Center with a four-year pediatric residency, where he was Chief Pediatric Resident in his final year. He then came to Children's Hospital at Montefiore for a pediatric critical care fellowship, which he completed in 2017.</p><p>Dr. Shlomovich’s research interests are in the use of artificial liver support technology, as well as the care of children in liver failure before and after transplantation. In addition, he investigates the safety and efficiency of the transportation of critically ill children. He has shared his research through peer-reviewed journals and abstracts, and is an ad hoc reviewer for BMC Nephrology.</p><p>Dr. Shlomovich is board certified in general pediatrics and pediatric critical care medicine. He is a member of the Society of Critical Care Medicine and the American Academy of Pediatrics.</p>
Matthew D. Shaines
<p>Dr. Matthew Shaines completed a medical degree at SUNY Downstate Medical Center - Brooklyn and an internal medicine residency at Montefiore/Einstein. He was then recruited to the Einstein faculty at Montefiore and became one of the initial group of hospitalists who founded the Teaching Hospitalist Program at Montefiore in 2004.</p>
<p>Dr. Shaines has served as Assistant Director of the Hospitalist Service, managing the Moses Teaching Hospitalist Program; founding Director of the Medicine Consult Service, creating a dedicated medicine consult rotation for the housestaff, with a mission of high quality service and education on topics pertaining to consultative and perioperative medicine; Associate Program Director for the Internal Medicine Residency Program, serving as a liaison between the program and the Division of Hospital Medicine. In 2018 he was appointed as the Associate Chief of Hospital Medicine for Education.</p>
<p>His teaching and academic interests are in clinical reasoning, quality improvement and faculty development. He serves as the lead vignette reviewer for Montefiore’s annual Division of General Internal Medicine/Division of Hospital Medicine SGIM/SHM scholarly review process, which helps to review and critique abstracts, posters and oral presentations prior to submission.</p>
Jonathan M. Schwartz
<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>
<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL. High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV. Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O’Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1, <strong>Schwartz JM,</strong> Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H,Dieterich DT, Branch AD, Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther. 2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL. Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma. In Rose BD, editor. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr. Clinical features, diagnosis, and screening for primary hepatocellular carcinoma. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr. Nonsurgical therapies for localized hepatocellular carcinoma. Up to date, Inc. Wellesley, MA, Updated 2014.<strong> </strong></li>
<li><strong>Schwartz JM</strong>. Approach to the patient with a focal liver lesion. Up to date Inc Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM. </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF. Prevalence and Natural History of Alcoholic Liver Disease. Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p> </p>
Shawn K. Samuel
Evelyn M. Rondinel
Yolanda Rivas
Dr. Rivas graduated from the University of Carabobo School of Medicine in Valencia, Venezuela, where she also spent her internship. After serving as a surgery assistant at Guerra Mendez Medical Center in Valencia, Dr. Rivas completed her Pediatric Residency at SUNY Health Science Center in Brooklyn and her Pediatric Gastroenterology and Nutrition Fellowship at Children?s Hospital at Montefiore. She directs the Pediatric Gastroenterology and Nutrition Fellowship Program at The Children's Hospital at Montefiore.